The MedTech Startup Podcast: CEO Mike Kujak
Francis Medical CEO Mike Kujak shares the highs and lows of being the CEO of a medtech startup and provides a window into the journey at Francis Medical.
November 2023
Minnesota Physician Article: Vanquish Water Vapor Ablation System
Vanquish Water Vapor Ablation System featured in the October 2023 Minnesota Physician Journal
August 2023
Press Release: Francis Medical Receives U.S. FDA Breakthrough Device Designation for Vanquish Minimally Invasive Prostate Cancer Therapy
August 1, 2023: Francis Medical today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Vanquish minimally invasive water vapor ablation therapy.
July 2023
Press Release: Francis Medical Announces First Patient Treated in VAPOR 2 Pivotal Study for Water Vapor Ablation of Prostate Cancer
July 19, 2023: Francis Medical today announced the first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapor ablation therapy for managing prostate cancer.
January 2023
Francis Medical Appoints Andrew Cleeland to Board of Directors
January 26, 2023: Francis Medical has appointed to its board of directors Andrew Cleeland, a leader with extensive experience in healthcare innovation and the development and deployment of new medical technologies.
April 2022
OnFocus Podcast: Michael Hoey
Francis Medical Founder and Chief Technology Officer, Michael Hoey, joins The Focal Therapy Clinic OnFocus podcast to discuss a new approach to focal therapy, water vapor therapy, and its adoption into medical practice.
September 2021
Press Release: Francis Medical Announces Close of $55 Million Series B Equity Financing
September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022.
June 2021
Press Release: Francis Medical Announces Positive Data from VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer
June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments.
March 2021
For the Record with Michael Hoey, Founder and CTO, Francis Medical
In an interview for Medical Alley's "For the Record," the founder and CTO of Francis Medical, Michael Hoey, shares why he sought a more compassionate approach for treating prostate cancer and how he discovered water vapor technology. He also gives a window into how things are progressing at Francis Medical...
October 2020
Maple Grove Medical Device Company Shares How They are Surviving During COVID-19
September 30, 2020: CCX Media visited Francis Medical to interview President and CEO Mike Kujak, and get an inside look at how Francis Medical is thriving and moving forward during the COVID-19 pandemic. This two-minute video includes recent news about a $4M investment by Coloplast.
September 2020
Press Release: Francis Medical Adds Urology Company Coloplast to Its Roster of Investors
September 29, 2020: Francis Medical Adds Urology Company Coloplast to Its Roster of Investors. The $4 million equity investment will support the company in optimizing its product design and executing a pivotal U.S. study.
August 2020
How Water Vapor Therapy Works
This video demonstrates how water vapor therapy will provide a revolutionary new prostate cancer treatment that is tough on prostate cancer yet gentle on patients.
June 2020
Maple Grove Medical Device Company Pioneers New Treatment For Prostate Cancer
June 17, 2020: CCX Media visited Francis Medical for exclusive interviews with CEO and President, Mike Kujak, and Founder and CTO, Michael Hoey. Their two-minute video includes an explanation of our revolutionary water vapor therapy, as well as plans for the future, including our VAPOR 1 clinical study.
Press Release: Francis Medical Announces First Patient Enrolled in VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer
June 9, 2020: Francis Medical, Inc. announces the enrollment of their first patient in the company’s VAPOR 1 clinical study, an early feasibility study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for the treatment of prostate cancer.
April 2020
Francis Medical Moving Forward in the Age of COVID-19
On the heels of successful patient treatments in Panama City, Panama, Francis Medical is overcoming challenges brought on by the COVID-19 pandemic to bring their ground-breaking water vapor technology to men dealing with prostate cancer.